Introduction
Numerous studies have investigated the impact of hormonal treatment on HIV acquisition, transmission and/or disease progression [1, 2] . Experimental observations have provided evidence that progesterone-based therapies can increase viral replication either by directly altering HIV-1 transcriptional activation and/or through regulation of cytokine and chemokine secretion [1] [2] [3] . Clinical studies have, however, provided conflicting results [4] [5] [6] [7] .
Case study
In December 2008, a 38-year-old woman from Ivory Coast who was diagnosed with HIV infection in 1999 experienced low blood haemoglobin concentrations (8.5 mg/dL) during a routine outpatient visit. Blood analysis revealed optimal response to HAART (HIV viral load <37 copies/mL, CD4 count: 600 cells/μL). She was receiving a combination of zidovudine, didanosine, and ritonavir-boosted lopinavir (LPV). As a first step, zidovudine and didanosine were replaced by tenovofir (TDF) plus emtritcitabine, with a transient recovery of haemoglobin concentration (9.6 mg/dL on May 2009). However, on July 2009 haemoglobin dropped to 8.5 mg/dL. The patient started a daily supplementation with iron sulphate, with a significant improvement in blood haemoglobin levels (consistently >10 mg/dL up to the end of 2009). Viral load remained undetectable (<37 copies/mL, see Fig. 1 ). On January 2010, the concentration of haemoglobin dropped suddenly to 8.6 mg/dL. The patient also presented excessive menstrual bleeding with methrorragia and reported episodes of menorrhagia. Therefore, in agreement with the gynaecologist, on February 2010 we started hormonal treatment with the progesterone-only formulation desogestrel (75 μg/day). At the next outpatient visit (March 2010), blood analyses revealed improved haemoglobin levels (9.3 mg/dL) and optimal erythrocyte count (4.65×10 6 cells/μL). The patient also reported a regularization of the blood loss during the last menstrual cycle, indicating a rapid resolution of methrorragia. This was, however, associated with a sudden immunologic and virologic failure (HIV RNA 15410 copies/ mL, CD4 count 344 cells/mm 3 , 12.5%). This acute event was initially attributed to poor compliance with therapy, despite the fact that for the past 10 years the patient had always shown optimal adherence to HAART. Blood samples were drawn for the assessment of plasma concentrations of LPV, TDF, ritonavir, and for genotyping resistance tests to HAART. Trough plasma concentrations of LPV, TDF and ritonavir were within the therapeutic range (4304, 23.0, and 140 ng/mL, respectively) [8, 9] . No HIV-drug-resistant variants were detected. The patient was not taking St. John's wort, grapefruit juice, or other substances known to affect HAART disposition. Taken together, these findings allowed us to exclude inadequate drug exposure due to poor compliance to HAART therapy and/or unexpected drug interactions as causes for the observed viral breakthrough.
Desogestrel is a prodrug that is activated to 3-ketodesogestrel by CYP2C9 and CYP3A4, two polymorphic enzymes also involved in the metabolism of the active progestin derivative [10] . Additional blood samples were collected for pharmacogenetic analyses to assess the patient's genetic background. According to pyrosequencing analysis, the patient was wild type for CYP2C9, but homozygous mutated for CYP3A5*3 and CYP3A4*1B, two allelic variants associated with absent/impaired enzyme activity [11] . Given the potential involvement of the CYP3A system in the activation of desogestrel [10] , our patient might be eventually overexposed to 3-keto-desogestrel despite standard daily dose regimens. Nevertheless, the additional contribution of concomitant administration of LPV/ritonavir-an inducer of CYP2C9 [12] -on desogestrel activation can not be ruled out. As a potential limitation of the present report, no data were available on plasma desogestrel/3-keto-desogestrel concentrations.
We decided to continue desogestrel treatment strictly monitoring the immunological status of our patient. As shown in Fig. 1 , both CD4 and viral mRNA counts gradually recovered in the next weeks after the acute event, while the patient was still taking desogestrel. An additional assessment of LPV, TDF, and ritonavir trough concentrations was carried out in April 2010, but again the levels measured (4160, 31.5, 203 ng/mL, respectively) exceeded the suggested minimum target concentration [8, 9] . Desogestrel was discontinued in the first week of May 2010 (as previously planned with the gynaecologist), with a further improvement in the HIV viral load and CD4 count ( Fig. 1) . At the last recorded visit (September 2010), the patient showed optimal immune reactivity towards HIV infection (HIV RNA <37 copies/mL, CD4 count 518 cells/mm 3 , 23.5%), no clinical signs of anaemia (haemoglobin 10.7 mg/dL, erythrocytes 4.0×10 6 cells/μL), sustained normalisation of the menstrual cycle with no further episodes of methrorragia/menorrhagia, and a most favourable exposure to HAART (LPV 2217 ng/mL, TDF 39.8 ng/mL, ritonavir 147 ng/mL).
Discussion
A variety of mechanisms can potentially explain the observed effects of desogestrel treatment on HIV replication. Hughes et al. [13] demonstrated that progesterone inhibits secretion of interferon-alpha from dendritic cells. Others have shown that progesterone-based therapies also cause a shift towards a Th2 humoural response, leading to a shift away from the Th1 cell-mediated response and weakening the mechanism for clearance of HIV-infected CD4 + T cells [1, 2] . From a clinical standpoint, our patient remained asymptomatic, with no clinical signs of disease progression despite the increase in viral load and decrease in CD4 count observed transiently after starting desogestrel. The immunologic status progressively improved and returned to baseline value at the end of desogestrel therapy. This case provides clinical evidence that progesterone-based therapy can alter HIV viral dynamics. However, this effect seemed to be 'auto-recovered', not requiring changes in the HAART therapy. The long term implications of this observation are unknown and require further study. Whereas no general recommendation can be drawn from a single case report, our observation nevertheless suggests that attention ought to be taken when prescribing progestinic hormones to HIV-infected women.
